News
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs.
7hon MSN
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that ...
Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
Everyday Health on MSN2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback